DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 3,245 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $61.23, for a total transaction of $198,691.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew K. Balo also recently made the following trade(s):

  • On Wednesday, November 29th, Andrew K. Balo sold 6,490 shares of DexCom stock. The stock was sold at an average price of $60.00, for a total transaction of $389,400.00.

Shares of DexCom, Inc. (DXCM) traded up $1.26 during trading on Wednesday, hitting $58.51. The company had a trading volume of 1,206,664 shares, compared to its average volume of 1,456,273. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom, Inc. has a one year low of $42.62 and a one year high of $88.80.

Several research firms recently weighed in on DXCM. BidaskClub upgraded shares of DexCom from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. BMO Capital Markets upped their target price on DexCom to $74.00 and gave the stock an “outperform” rating in a research note on Tuesday. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $87.00 target price on shares of DexCom in a research note on Thursday, September 28th. Northland Securities initiated coverage on DexCom in a research note on Tuesday, September 26th. They issued an “outperform” rating and a $85.00 target price for the company. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $57.00 target price (down previously from $85.00) on shares of DexCom in a research note on Friday, September 29th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $71.36.

Several institutional investors have recently made changes to their positions in the stock. Advisor Group Inc. raised its holdings in DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after purchasing an additional 837 shares in the last quarter. IFP Advisors Inc raised its holdings in DexCom by 30.5% in the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after purchasing an additional 568 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in DexCom by 9.2% in the second quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after purchasing an additional 250 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in DexCom by 12.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after purchasing an additional 354 shares in the last quarter. Finally, Zions Bancorporation raised its holdings in DexCom by 36,222.2% in the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after purchasing an additional 3,260 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/13/dexcom-inc-dxcm-evp-sells-198691-35-in-stock.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.